Mission Wealth Management LP Lowers Stock Holdings in Becton Dickinson and Co (NYSE:BDX)

Mission Wealth Management LP lessened its stake in Becton Dickinson and Co (NYSE:BDX) by 2.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,400 shares of the medical instruments supplier’s stock after selling 39 shares during the period. Mission Wealth Management LP’s holdings in Becton Dickinson and were worth $381,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Allworth Financial LP boosted its holdings in shares of Becton Dickinson and by 386.4% in the third quarter. Allworth Financial LP now owns 107 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 85 shares in the last quarter. Northwest Investment Counselors LLC purchased a new position in Becton Dickinson and during the third quarter worth about $27,000. Liberty Wealth Management LLC lifted its position in Becton Dickinson and by 293.1% in the third quarter. Liberty Wealth Management LLC now owns 114 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 85 shares during the period. CX Institutional acquired a new stake in Becton Dickinson and in the third quarter valued at about $31,000. Finally, North Star Investment Management Corp. acquired a new stake in Becton Dickinson and in the third quarter valued at about $45,000. Hedge funds and other institutional investors own 84.49% of the company’s stock.

BDX has been the topic of several recent analyst reports. JPMorgan Chase & Co. boosted their target price on Becton Dickinson and from $285.00 to $300.00 and gave the stock an “overweight” rating in a research report on Friday, December 20th. Barclays cut Becton Dickinson and from an “overweight” rating to an “equal weight” rating and set a $275.00 price target for the company. in a report on Wednesday, January 8th. Morgan Stanley lifted their price target on Becton Dickinson and from $261.00 to $287.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 17th. Stifel Nicolaus lifted their price target on Becton Dickinson and from $275.00 to $295.00 and gave the company a “buy” rating in a research note on Monday, December 16th. Finally, KeyCorp raised their target price on Becton Dickinson and from $284.00 to $298.00 and gave the company an “overweight” rating in a report on Wednesday. Six equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $281.90.

BDX opened at $277.53 on Wednesday. Becton Dickinson and Co has a 1-year low of $221.47 and a 1-year high of $279.62. The stock has a market cap of $74.94 billion, a P/E ratio of 71.16, a P/E/G ratio of 1.98 and a beta of 1.07. The stock’s 50 day simple moving average is $270.08 and its 200 day simple moving average is $256.83. The company has a debt-to-equity ratio of 0.86, a current ratio of 1.18 and a quick ratio of 0.72.

Becton Dickinson and (NYSE:BDX) last issued its quarterly earnings data on Tuesday, November 5th. The medical instruments supplier reported $3.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.30 by $0.01. The firm had revenue of $4.58 billion during the quarter, compared to analysts’ expectations of $4.57 billion. Becton Dickinson and had a return on equity of 15.52% and a net margin of 6.84%. Becton Dickinson and’s revenue was up 4.1% on a year-over-year basis. During the same period in the previous year, the firm posted $2.93 earnings per share. Research analysts expect that Becton Dickinson and Co will post 12.57 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 31st. Stockholders of record on Tuesday, December 10th were given a $0.79 dividend. The ex-dividend date was Monday, December 9th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 1.14%. This is a boost from Becton Dickinson and’s previous quarterly dividend of $0.77. Becton Dickinson and’s dividend payout ratio (DPR) is currently 27.05%.

In other news, CEO Vincent A. Forlenza sold 11,626 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $265.57, for a total value of $3,087,516.82. Following the sale, the chief executive officer now directly owns 225,393 shares in the company, valued at $59,857,619.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Vincent A. Forlenza sold 33,365 shares of the firm’s stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $271.28, for a total transaction of $9,051,257.20. Following the transaction, the chief executive officer now directly owns 254,312 shares of the company’s stock, valued at $68,989,759.36. The disclosure for this sale can be found here. In the last 90 days, insiders sold 91,231 shares of company stock valued at $24,787,690. Company insiders own 0.12% of the company’s stock.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: Why are percentage decliners important?

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.